Active substance
Moclobemide
- SFDA 4
- Health Canada 4
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| AURORIX 150MG TAB | 150 mg | Tablet · Oral use | 30 Blister | SAR 41.40 | NCE · Prescription | MEDA PHARMA GmbH & Co KG | Valid |
| AURORIX 300MG TAB | 300 mg | Tablet · Oral use | 30 Blister | SAR 67.25 | NCE · Prescription | MEDA PHARMA GmbH & Co KG | Valid |
| AURORIX 150MG TAB | 150 mg | Tablet · Oral use | 30 Blister | SAR 58.65 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
| AURORIX 300MG TAB | 300 mg | Tablet · Oral use | 30 Blister | SAR 90.65 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE BIPOLAR I DEPRESSION; ANXIETY DISORDERS; DEPRESSION
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MANERIX | 02166747 | 300 MG | TABLET · ORAL | BAUSCH HEALTH, CANADA INC. |
| MOCLOBEMIDE | 02232148 | 100 MG | TABLET · ORAL | AA PHARMA INC |
| MOCLOBEMIDE | 02232150 | 150 MG | TABLET · ORAL | AA PHARMA INC |
| MOCLOBEMIDE | 02240456 | 300 MG | TABLET · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Moclobemide 150mg tablets | £9.33 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Moclobemide 300mg tablets | £13.99 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.